Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study | Nature Medicine
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study

Nature Medicine volume 14, pages 822–827 (2008)Cite this article

Abstract

Although prognostic gene expression signatures for survival in early-stage lung cancer have been proposed, for clinical application, it is critical to establish their performance across different subject populations and in different laboratories. Here we report a large, training–testing, multi-site, blinded validation study to characterize the performance of several prognostic models based on gene expression for 442 lung adenocarcinomas. The hypotheses proposed examined whether microarray measurements of gene expression either alone or combined with basic clinical covariates (stage, age, sex) could be used to predict overall survival in lung cancer subjects. Several models examined produced risk scores that substantially correlated with actual subject outcome. Most methods performed better with clinical data, supporting the combined use of clinical and molecular information when building prognostic models for early-stage lung cancer. This study also provides the largest available set of microarray data with extensive pathological and clinical annotation for lung adenocarcinomas.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Classifier performance.
Figure 2: Kaplan-Meier estimates of the survivor function for method A on each validation data set for the four hypotheses.
Figure 3: Kaplan-Meier estimates of the survivor function for method A (cross-validated) on training sets UM and MSK.

Similar content being viewed by others

References

  1. Jemal, A. et al. Cancer Statistics 2006. CA Cancer J. Clin. 56, 106–130 (2006).

    Article  Google Scholar 

  2. Booth, C.M. & Shepherd, F.A. Adjuvant chemotherapy for resected non-small cell lung cancer. J. Thorac. Oncol. 2, 180–187 (2006).

    Article  Google Scholar 

  3. Gandara, D.R., Wakelee, H., Calhoun, R. & Jablons, D. Adjuvant chemotherapy of stage I non-small cell lung cancer in North America. J. Thorac. Oncol. 7 (suppl. 3), S125–S127 (2007).

    Article  Google Scholar 

  4. Shepherd, F.A. et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123–132 (2005).

    Article  CAS  Google Scholar 

  5. Bhattacharjee, A. et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. USA 98, 13790–13795 (2001).

    Article  CAS  Google Scholar 

  6. Garber, M.E. et al. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl. Acad. Sci. USA 98, 13784–13789 (2001).

    Article  CAS  Google Scholar 

  7. Beer, D.G. et al. Gene-expression profiles predict survival of subjects with lung adenocarcinoma. Nat. Med. 8, 816–824 (2002).

    Article  CAS  Google Scholar 

  8. Wigle, D.A. et al. Molecular profiling of non–small cell lung cancer and correlation with disease-free survival. Cancer Res. 62, 3005–3008 (2002).

    CAS  PubMed  Google Scholar 

  9. Potti, A. et al. A genomic strategy to refine prognosis in early-stage non–small-cell lung cancer. N. Engl. J. Med. 355, 570–580 (2006).

    Article  CAS  Google Scholar 

  10. Chen, H.Y. et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med. 356, 11–20 (2007).

    Article  CAS  Google Scholar 

  11. Lu, Y. et al. A gene expression signature predicts survival of subjects with stage I non-small cell lung cancer. PLoS Med. 12, e467 (2006).

    Article  Google Scholar 

  12. Dobbin, K.K. et al. Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin. Cancer Res. 11, 565–572 (2005).

    CAS  Google Scholar 

  13. Fry, W.A., Phillips, J.L. & Menck, H.R. Ten-year survey of lung cancer treatments and survival in hospitals in the United States. Cancer 86, 1867–1876 (1999).

    Article  CAS  Google Scholar 

  14. Li, C. & Wong, W.H. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl. Acad. Sci. USA 98, 31–36 (2001).

    Article  CAS  Google Scholar 

  15. Moran, C.J. et al. Rantes expression by lung adenocarcinomas is a predictor of survival in stage I subjects. Clin. Cancer Res. 8, 3803–3812 (2002).

    CAS  PubMed  Google Scholar 

  16. Stephenson, A.J. et al. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 104, 290–298 (2005).

    Article  CAS  Google Scholar 

  17. Sotiriou, C. & Piccart, M.J. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to subject care? Nat. Rev. Cancer 7, 545–553 (2007).

    Article  CAS  Google Scholar 

  18. Gonen, M. & Heller, G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika 92, 965–970 (2005).

    Article  Google Scholar 

Download references

Acknowledgements

We thank M. Orringer, A. Pickens, F. Taylor, N. Liu, D. Lau, M. Whitehead, L. Chen, L. Vargas, Y. Xiao, M. Maddaus and C. Hoang. We thank M. Heiskanen, L. Liu, D. Reeves and S. Whitley from the US National Cancer Institute Center for Bioinformatics and W. Ricker from Information Management Services for assistance with development of the lung study database and data management. We thank D. Sawyer, J.M. Askew and A. Vaughn of the Cancer and Leukemia Group B Statistical Center, Duke University for quality control of the clinical data. We thank Affymetrix for technical support. This work was supported by US National Cancer Institute grants CA84953, CA84999, CA84995, CA85052 and CA46592 and contracts 263-MQ-319735, 263-MQ-319740, 263-MQ-319746 and 263-MQ-510430 and support from the Canadian Cancer Society.

Author information

Author notes

  1. Kerby Shedden, Jeremy M G Taylor, Steven A Enkemann, Ming-Sound Tsao, Timothy J Yeatman, William L Gerald, Steven Eschrich, Igor Jurisica, Venkatraman E Seshan, Matthew Meyerson, Rork Kuick, Kevin K Dobbin, Tracy Lively, James W Jacobson and David G Beer: Writing Committee members.

Authors and Affiliations

  1. Department of Statistics, 1085 South University, University of Michigan, Ann Arbor, 48109, Michigan, USA

    Kerby Shedden

  2. Cancer Center, 1500 East Medical Center Drive, University of Michigan, Ann Arbor, 48109, Michigan, USA

    Kerby Shedden, Jeremy M G Taylor, David E Misek, Andrew C Chang, Samir Hanash, Rork Kuick & David G Beer

  3. Department of Biostatistics, 1420 Washington Heights, University of Michigan, Ann Arbor, 48109, Michigan, USA

    Jeremy M G Taylor

  4. Department of Surgery, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Avenue, Tampa, 33612, Florida, USA

    Steven A Enkemann, Timothy J Yeatman, Steven Eschrich, Michael Gruidl & Anupama Sharma

  5. University Health Network, Ontario Cancer Institute and Princess Margaret Hospital, 610 University Avenue, Toronto, M5G 2M9, Ontario, Canada

    Ming-Sound Tsao, Igor Jurisica, Chang Qi Zhu, Daniel Strumpf & Frances A Shepherd

  6. Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, 10021, New York, USA

    William L Gerald, Janos Szoke, Maureen Zakowski, Valerie Rusch, Mark Kris, Agnes Viale, Noriko Motoi & William Travis

  7. Department of Pathology, University Hospital 2G332/0054, University of Michigan, Ann Arbor, 48109, Michigan, USA

    Thomas J Giordano

  8. Department of Surgery, 1150 West Medical Center Drive, University of Michigan, Ann Arbor, 48109, Michigan, USA

    David E Misek, Andrew C Chang & David G Beer

  9. National Cancer Institute of Canada Clinical Trials Group and Queen's University, 10 Stuart Street, Kingston, K7L 3N6, Ontario, Canada

    Keyue Ding & Lesley Seymour

  10. Department of Medical Oncology, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, 44 Binney Street, Boston, 02115, Massachusetts, USA

    Katsuhiko Naoki, Nathan Pennell, Barbara Weir, Roel Verhaak & Matthew Meyerson

  11. Broad Institute, 7 Cambridge Center, Cambridge, 02142, Massachusetts, USA

    Christine Ladd-Acosta, Todd Golub & Matthew Meyerson

  12. Department of Medicine, B-414 Clinical Center, Michigan State University, East Lansing, 48824, Michigan, USA

    Barbara Conley

  13. Columbia University, 722 West 168th Street, New York, 10032, New York, USA

    Venkatraman E Seshan

  14. Biometric Research Branch National Cancer Institute, EPN 8121A, 6130 Executive Boulevard, Rockville, 20852, Maryland, USA

    Kevin K Dobbin

  15. Cancer Diagnosis Program, National Cancer Institute, EPN 6035A, 6130 Executive Boulevard, Rockville, 20852, Maryland, USA

    Tracy Lively & James W Jacobson

Consortia

Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma

  • Kerby Shedden
  • , Jeremy M G Taylor
  • , Steven A Enkemann
  • , Ming-Sound Tsao
  • , Timothy J Yeatman
  • , William L Gerald
  • , Steven Eschrich
  • , Igor Jurisica
  • , Thomas J Giordano
  • , David E Misek
  • , Andrew C Chang
  • , Chang Qi Zhu
  • , Daniel Strumpf
  • , Samir Hanash
  • , Frances A Shepherd
  • , Keyue Ding
  • , Lesley Seymour
  • , Katsuhiko Naoki
  • , Nathan Pennell
  • , Barbara Weir
  • , Roel Verhaak
  • , Christine Ladd-Acosta
  • , Todd Golub
  • , Michael Gruidl
  • , Anupama Sharma
  • , Janos Szoke
  • , Maureen Zakowski
  • , Valerie Rusch
  • , Mark Kris
  • , Agnes Viale
  • , Noriko Motoi
  • , William Travis
  • , Barbara Conley
  • , Venkatraman E Seshan
  • , Matthew Meyerson
  • , Rork Kuick
  • , Kevin K Dobbin
  • , Tracy Lively
  • , James W Jacobson
  •  & David G Beer

Contributions

Writing Committee: K.S., J.M.G.T., S.A.E., M.S.T., T.J.Y., W.L.G., S.E., I.J., V.E.S., M.M., R.K., K.K.D., T.L., J.W.J. and D.G.B. Members of the Writing Committee participated in the planning, initiation, data generation, data analysis and manuscript preparation for the project.

Additional participants: T.J.G., D.E.M., A.C.C. and S.H. participated in aspects of sample collection and preparation, data generation and data analysis at the University of Michigan. C.Q.Z., D.S., F.A.S., K.D. and L.S. participated in aspects of sample collection and preparation, data generation and data analysis at the Ontario Cancer Institute. K.N., N.P., B.W., R.V., C.L.-A and T.G. participated in aspects of sample collection and preparation, data generation and data analysis at the Dana-Farber Cancer Institute and Broad Institute. M.G. assembled the clinical data at the H. Lee Moffitt Cancer Center. J.S., M.Z., V.R., M.K., A.V., N.M., W.T. and A.S. participated in aspects of sample collection and preparation, data generation and data analysis at Memorial Sloan-Kettering Cancer Center. B.C. participated in the planning and initiation of the study.

Corresponding authors

Correspondence to James W Jacobson or David G Beer.

Additional information

The consortium consists of the Writing Committee plus additional participants as detailed in the Author Contributions section.

Supplementary information

Supplementary Text and Figures

Supplementary Figs. 1 and 2 (PDF 2763 kb)

Supplementary Table 1

Supplementary Data (XLS 409 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma. Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14, 822–827 (2008). https://doi.org/10.1038/nm.1790

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.1790

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing